Actinium Pharmaceuticals Presents First-in-Human ATNM-400 Data in Prostate Cancer

Bitget2026/10/19 11:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Actinium Pharmaceuticals will present early Phase 1 ATNM-400 data in metastatic castration-resistant prostate cancer today at EANM in Vienna.
The ongoing first-in-human study evaluates an imaging counterpart to guide development and dosing of the HER3-targeted radiotherapy beyond PSMA-directed treatment.
A separate presentation will cover preclinical lung cancer studies testing ATNM-400 alone or with targeted therapies, supporting potential expansion across solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610190730PR_NEWS_USPR_____NY74920) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Actinium Pharmaceuticals Presents First-in-Human ATNM-400 Data in Prostate Cancer

You may also like

Crypto prices